A new article published in CC&R is demonstrating the clinical value of plasma Calprotectin as an early biomarker of bacterial infections

03. Oct 2017 | 3 min read

Recently, the Critical Care and Resuscitation (CC&R) Journal published an article demonstrating the advantage of Gentians assay for calprotectin in blood plasma for the prediction and diagnosis of bacterial infections in critically ill patients. The study was based on the prototype of Gentian's recently launched GCAL test.

Sepsis is potentially a life-threatening complication because of a serious infection, and is the leading source of morbidity and mortality worldwide. Early detection and initiation of antibiotic treatment in septic shock is of vital importance since it is associated with lower mortality.

"The article published in CC&R demonstrates that the predictive and diagnostic accuracy of plasma calprotectin in patients with bacterial infection could be superior to that of other traditional biomarkers. Moreover, calprotectin levels were increased in the blood of infected patients 24 h before the infection was suspected and antibiotic therapy was initiated. This suggests that the use of plasma calprotectin may prevent the unnecessary- and unwanted prescription of antibiotics, and as a result the associated problem with multi-resistant bacteria" says Aleksandra Mandic Havelka, Managing Director in Gentian Diagnostics AB. If used correctly plasma calprotectin could be a very valuable additional diagnostic tool to guide the appropriate initiation of antibiotic therapy and help doctors save the lives of critically ill patients.

The abstract of the article can be found here: https://www.ncbi.nlm.nih.gov/pubmed/28866970

For further information, please contact:

Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: Bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117



Gentian Diagnostics AS is a medical diagnostics company listed on Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME".

Gentian is headquartered in Moss, Norway, with a representative office in China and distribution subsidiaries in Sweden and USA.

Gentian designs, develops and markets in vitro diagnostic reagents (IVD) based on its proprietary Nanosense technology. The goal is to offer efficient and accurate reagents for major clinical chemistry platforms with a focus within the areas of kidney disease, cardiac disease, inflammation and veterinary medicine. The Nanosense technology will enable users to move assays from low volume immunology platforms to fully automated, high throughput instruments with shorter turnaround times, better workflow and improved cost efficiency.

MeldingsID:  435862

You may also read

Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..